BioNTech Historical Financial Ratios

BNTX Stock  USD 113.13  4.90  4.53%   
BioNTech is presently reporting on over 122 different financial statement accounts. To analyze all of these accounts together requires a lot of time and effort. However, using these accounts to derive some meaningful and actionable indicators such as Dividend Yield of 0.0111, PTB Ratio of 1.2 or Days Sales Outstanding of 235 will help investors to properly organize and evaluate BioNTech SE financial condition quickly.
  
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in BioNTech SE. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.

About BioNTech Financial Ratios Analysis

BioNTech SEFinancial ratios are relationships based on a company's financial information. They can serve as useful tools to evaluate BioNTech investment potential. Financial ratio analysis can also be defined as the process of presenting financial ratios, which are mathematical indicators calculated by comparing key financial information appearing on BioNTech financial statements. Financial ratios are useful tools that help investors analyze and compare relationships between different pieces of financial information across BioNTech history.

BioNTech Financial Ratios Chart

At this time, BioNTech's POCF Ratio is fairly stable compared to the past year. Capex To Operating Cash Flow is likely to rise to 0.14 in 2024, whereas Price To Sales Ratio is likely to drop 5.77 in 2024.
Add Fundamental
Price To Sales RatioDividend Yield
Ptb RatioDays Sales Outstanding
Book Value Per ShareFree Cash Flow Yield
Invested CapitalOperating Cash Flow Per Share
Average PayablesStock Based Compensation To Revenue
Capex To DepreciationPb Ratio
Ev To SalesFree Cash Flow Per Share
RoicInventory Turnover
Net Income Per ShareDays Of Inventory On Hand
Payables TurnoverSales General And Administrative To Revenue
Average InventoryResearch And Ddevelopement To Revenue
Capex To RevenueCash Per Share
PocfratioInterest Coverage
Payout RatioCapex To Operating Cash Flow
Pfcf RatioDays Payables Outstanding
Net Current Asset ValueIncome Quality
RoeTangible Asset Value
Ev To Operating Cash FlowPe Ratio
Return On Tangible AssetsEv To Free Cash Flow
Earnings YieldIntangibles To Total Assets
Net Debt To E B I T D ACurrent Ratio
Tangible Book Value Per ShareReceivables Turnover
Graham NumberShareholders Equity Per Share
Debt To EquityCapex Per Share
Graham Net NetAverage Receivables
Revenue Per ShareInterest Debt Per Share
Debt To AssetsEnterprise Value Over E B I T D A
Short Term Coverage RatiosPrice Earnings Ratio
Operating CyclePrice Book Value Ratio
Price Earnings To Growth RatioDays Of Payables Outstanding
Dividend Payout RatioPrice To Operating Cash Flows Ratio
Price To Free Cash Flows RatioPretax Profit Margin
Ebt Per EbitOperating Profit Margin
Effective Tax RateCompany Equity Multiplier
Long Term Debt To CapitalizationTotal Debt To Capitalization
Return On Capital EmployedDebt Equity Ratio
Ebit Per RevenueQuick Ratio
Dividend Paid And Capex Coverage RatioNet Income Per E B T
Cash RatioCash Conversion Cycle
Operating Cash Flow Sales RatioDays Of Inventory Outstanding
Days Of Sales OutstandingFree Cash Flow Operating Cash Flow Ratio
Cash Flow Coverage RatiosPrice To Book Ratio
Fixed Asset TurnoverCapital Expenditure Coverage Ratio
Price Cash Flow RatioEnterprise Value Multiple
Debt RatioCash Flow To Debt Ratio
Price Sales RatioReturn On Assets
Asset TurnoverNet Profit Margin
Gross Profit MarginPrice Fair Value
Return On Equity

Price To Sales Ratio

Price to Sales Ratio is figured by comparing BioNTech SE stock price to its revenues. An advantage to using Price to Sales ratio is that it is based on BioNTech sales, a figure that is much harder to manipulate than other BioNTech SE multiples. Because sales tend to be more stable P/S ratio can be a good tool for screening cyclical companies fluctuating earnings patterns. A valuation ratio that compares a company's stock price to its revenues, calculated by dividing the company's market cap by its total sales or revenue over a 12-month period.

Dividend Yield

Dividend Yield is BioNTech SE dividend as a percentage of BioNTech stock price. BioNTech SE dividend yield is a measure of BioNTech stock productivity, which can be interpreted as interest rate earned on an BioNTech investment. A financial ratio that shows how much a company pays out in dividends each year relative to its stock price, calculated as annual dividends per share divided by price per share.

Invested Capital

Invested capital represents the total cash investment that shareholders and debt holders have contributed to BioNTech SE. There are two different methods for calculating BioNTech SE invested capital: operating approach and financing approach. Understanding BioNTech invested capital allows investors to calculate measures of performance such as return on invested capital or return on capital employed.

Ev To Sales

The Enterprise Value to Sales ratio, a valuation metric used to compare the value of a company, including debt and excluding cash, to its sales revenue.
Most ratios from BioNTech's fundamentals are interrelated and interconnected. However, analyzing fundamentals ratios one by one will only give a small insight into BioNTech SE current financial condition. On the other hand, looking into the entire matrix of fundamentals ratios, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in BioNTech SE. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.
At this time, BioNTech's POCF Ratio is fairly stable compared to the past year. Capex To Operating Cash Flow is likely to rise to 0.14 in 2024, whereas Price To Sales Ratio is likely to drop 5.77 in 2024.
 2023 2024 (projected)
Dividend Yield0.01250.0111
Price To Sales Ratio6.075.77

BioNTech fundamentals Correlations

0.53-0.61-0.57-0.89-0.78-0.720.53-0.611.0-0.70.40.81-0.7-0.65-0.50.87-0.78-0.1-0.590.53-0.28-0.430.29-0.520.49
0.53-0.33-0.48-0.71-0.53-0.390.18-0.330.55-0.350.410.70.05-0.940.210.43-0.8-0.140.051.0-0.3-0.21-0.33-0.930.41
-0.61-0.330.870.570.490.42-0.971.0-0.630.41-0.93-0.670.420.430.57-0.870.5-0.250.38-0.33-0.050.02-0.720.37-0.96
-0.57-0.480.870.660.50.39-0.880.87-0.580.37-0.77-0.850.420.590.54-0.860.58-0.280.45-0.48-0.030.06-0.570.45-0.82
-0.89-0.710.570.660.920.84-0.470.57-0.90.82-0.44-0.90.590.810.42-0.810.960.20.4-0.710.430.45-0.170.73-0.51
-0.78-0.530.490.50.920.98-0.390.49-0.790.97-0.39-0.750.580.610.43-0.720.920.130.21-0.530.330.27-0.230.59-0.45
-0.72-0.390.420.390.840.98-0.330.42-0.721.0-0.32-0.630.610.470.48-0.650.840.180.2-0.390.350.28-0.270.46-0.37
0.530.18-0.97-0.88-0.47-0.39-0.33-0.970.54-0.330.830.61-0.51-0.27-0.70.85-0.350.3-0.50.180.11-0.020.84-0.170.88
-0.61-0.331.00.870.570.490.42-0.97-0.630.41-0.93-0.670.420.430.57-0.870.5-0.250.38-0.33-0.050.02-0.720.37-0.96
1.00.55-0.63-0.58-0.9-0.79-0.720.54-0.63-0.70.440.82-0.68-0.67-0.480.87-0.8-0.1-0.560.55-0.29-0.430.29-0.560.52
-0.7-0.350.410.370.820.971.0-0.330.41-0.7-0.3-0.60.620.420.49-0.640.810.170.2-0.350.340.27-0.290.42-0.35
0.40.41-0.93-0.77-0.44-0.39-0.320.83-0.930.44-0.30.53-0.08-0.47-0.270.68-0.480.26-0.020.410.080.140.52-0.50.99
0.810.7-0.67-0.85-0.9-0.75-0.630.61-0.670.82-0.60.53-0.5-0.83-0.410.88-0.840.13-0.450.7-0.12-0.210.25-0.660.6
-0.70.050.420.420.590.580.61-0.510.42-0.680.62-0.08-0.50.070.92-0.680.350.20.870.050.330.56-0.64-0.09-0.19
-0.65-0.940.430.590.810.610.47-0.270.43-0.670.42-0.47-0.830.07-0.1-0.560.870.110.07-0.940.30.250.240.95-0.48
-0.50.210.570.540.420.430.48-0.70.57-0.480.49-0.27-0.410.92-0.1-0.670.180.040.80.210.180.38-0.87-0.23-0.36
0.870.43-0.87-0.86-0.81-0.72-0.650.85-0.870.87-0.640.680.88-0.68-0.56-0.67-0.690.21-0.590.43-0.02-0.170.62-0.410.76
-0.78-0.80.50.580.960.920.84-0.350.5-0.80.81-0.48-0.840.350.870.18-0.690.160.11-0.80.370.290.00.85-0.52
-0.1-0.14-0.25-0.280.20.130.180.3-0.25-0.10.170.260.130.20.110.040.210.160.17-0.140.970.880.270.250.25
-0.590.050.380.450.40.210.2-0.50.38-0.560.2-0.02-0.450.870.070.8-0.590.110.170.050.270.6-0.56-0.15-0.13
0.531.0-0.33-0.48-0.71-0.53-0.390.18-0.330.55-0.350.410.70.05-0.940.210.43-0.8-0.140.05-0.3-0.21-0.33-0.930.41
-0.28-0.3-0.05-0.030.430.330.350.11-0.05-0.290.340.08-0.120.330.30.18-0.020.370.970.27-0.30.920.150.40.06
-0.43-0.210.020.060.450.270.28-0.020.02-0.430.270.14-0.210.560.250.38-0.170.290.880.6-0.210.920.00.250.08
0.29-0.33-0.72-0.57-0.17-0.23-0.270.84-0.720.29-0.290.520.25-0.640.24-0.870.620.00.27-0.56-0.330.150.00.320.58
-0.52-0.930.370.450.730.590.46-0.170.37-0.560.42-0.5-0.66-0.090.95-0.23-0.410.850.25-0.15-0.930.40.250.32-0.49
0.490.41-0.96-0.82-0.51-0.45-0.370.88-0.960.52-0.350.990.6-0.19-0.48-0.360.76-0.520.25-0.130.410.060.080.58-0.49
Click cells to compare fundamentals

BioNTech Account Relationship Matchups

BioNTech fundamentals Accounts

201920202021202220232024 (projected)
Price To Sales Ratio58.8432.562.911.976.075.77
Ptb Ratio12.9511.454.651.71.151.2
Book Value Per Share2.335.8348.7482.4383.3587.52
Free Cash Flow Yield(0.0422)(0.006299)0.01330.390.20.21
Operating Cash Flow Per Share(0.94)(0.0572)3.6555.8122.1123.22
Stock Based Compensation To Revenue0.280.06660.0049480.0062740.01350.0128
Capex To Depreciation2.12.212.052.953.853.41
Pb Ratio12.9511.454.651.71.151.2
Ev To Sales54.730.552.841.183.082.92
Free Cash Flow Per Share(1.27)(0.42)3.0254.3119.2120.17
Roic(0.37)0.005330.860.460.02650.0251
Inventory Turnover20.810.997.6810.311.681.59
Net Income Per Share(0.85)0.064642.1838.783.833.64
Days Of Inventory On Hand17.5533.2347.5135.4217.67228.56
Payables Turnover11.96.8924.1322.21.691.61
Research And Ddevelopement To Revenue2.091.340.0054120.0067010.470.44
Cash Per Share2.465.728.557.8168.1371.54
Pocfratio(32.18)(1.2K)62.172.514.324.53
Interest Coverage(105.66)(1.27)2.8K668.9387.3983.02
Capex To Operating Cash Flow(0.36)(6.34)0.170.02680.130.14
Pfcf Ratio(23.7)(158.75)75.192.584.975.22
Days Payables Outstanding30.6853.0115.1316.44215.42226.19
Income Quality1.110.09240.05911.054.534.76
Roe(0.36)0.01110.870.470.0460.0437
Ev To Operating Cash Flow(29.92)(1.1K)60.611.512.192.3
Pe Ratio(35.66)1.0K5.373.6224.9323.68
Return On Tangible Assets(0.25)0.0070530.660.410.04260.0554
Ev To Free Cash Flow(22.03)(148.95)73.31.552.522.64
Earnings Yield(0.028)9.68E-40.190.280.04010.0487
Intangibles To Total Assets0.110.07050.01280.0094380.04970.0881
Net Debt To E B I T D A2.969.23(0.0927)(1.1)(10.52)(10.0)
Current Ratio4.052.754.337.439.439.9
Tangible Book Value Per Share1.915.1347.9281.5378.6482.57
Graham Number6.672.91215.09268.1884.7566.44
Shareholders Equity Per Share2.335.8348.7482.4383.3587.52

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for BioNTech Stock Analysis

When running BioNTech's price analysis, check to measure BioNTech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BioNTech is operating at the current time. Most of BioNTech's value examination focuses on studying past and present price action to predict the probability of BioNTech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BioNTech's price. Additionally, you may evaluate how the addition of BioNTech to your portfolios can decrease your overall portfolio volatility.